How Symbio Delivered Fast Recruitment & High Retention in a Global Phase 3 Psoriasis Trial

In this global Phase 3 moderate-to-severe plaque psoriasis trial, Symbio delivered rapid recruitment, strong retention, and exceptional startup efficiency across 30 sites. With 404 patients randomized in just ~4.2 months, a ~92% randomization rate, and ~94% patient retention, the program stayed on track despite strict eligibility criteria and ambitious timelines. See how specialized dermatology expertise made the difference.